Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older

Pneumococcal 13-valent Conjugate Vaccine Clinical Trial

Status Enrolling by invitation

Clinical Trial Summary

This study evaluates the safety of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older.120 Subjects will be equally divided into 4 groups,including 18 years and older,2-5 years old, 2 months old and 3 months old. Subjects aged 18 years and 2-5 years old will receive one dose of PCV13 vaccine,while subjects aged 2 and 3 months will receive 3 doses of PCV13 vaccine,injected at 2, 4, 6 months or 3、4、5 months respectively.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Pneumococcal 13-valent Conjugate Vaccine

• NCT number: NCT02544698
• Study type: Interventional
• Source: Beijing Chaoyang District Centre for Disease Control and Prevention
• Status: Enrolling by invitation
• Phase: Phase 1
• Start date: November 2015
• Completion date: December 2016